Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial.

Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S.

Hepat Mon. 2013 Dec 6;13(12):e14679. doi: 10.5812/hepatmon.14679. eCollection 2013.

2.

The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial.

Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E.

Hepat Mon. 2013 May 21;13(5):e9270. doi: 10.5812/hepatmon.9270. Print 2013 May.

3.

Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.

Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY.

J Zhejiang Univ Sci B. 2006 Aug;7(8):627-33.

4.

The effect of magnesium supplementation and weight loss on liver enzymes in patients with nonalcoholic fatty liver disease.

Karandish M, Tamimi M, Shayesteh AA, Haghighizadeh MH, Jalali MT.

J Res Med Sci. 2013 Jul;18(7):573-9.

5.

Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.

Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S.

Nutr Clin Pract. 2013 Feb;28(1):101-11. doi: 10.1177/0884533612454884. Epub 2012 Oct 5.

PMID:
23042833
6.

Insulin resistance and metabolic syndrome in patients with NAFLD but without diabetes: effect of a 6 month regime intervention.

Cankurtaran M, Tayfur O, Yavuz BB, Geyik S, Akhan O, Arslan S.

Acta Gastroenterol Belg. 2007 Jul-Sep;70(3):253-9.

PMID:
18074733
7.

[Relationship between liver fat content and liver enzymes in individuals with various statuses of glucose metabolism].

Bian H, Yan HM, Xia MF, Rao SX, Yao XZ, Zeng MS, Zhou J, Jia WP, Gao X.

Zhonghua Yi Xue Za Zhi. 2010 Dec 28;90(48):3385-90. Chinese.

PMID:
21223809
8.

Helicobacter pylori infection in patients with nonalcoholic fatty liver disease.

Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, Zavos C, Anastasiadou K, Terpos E.

Metabolism. 2013 Jan;62(1):121-6. doi: 10.1016/j.metabol.2012.06.007. Epub 2012 Jul 27.

PMID:
22841522
9.

Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation.

Gen R, Demir M, Ataseven H.

South Med J. 2010 Mar;103(3):190-6. doi: 10.1097/SMJ.0b013e3181cf373f.

PMID:
20134372
10.

Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study.

Polyzos SA, Nikolopoulos P, Stogianni A, Romiopoulos I, Katsinelos P, Kountouras J.

Arq Gastroenterol. 2014 Jul-Sep;51(3):261-8.

11.

Expression and significance of fat mass and obesity associated gene and forkhead transcription factor O1 in non-alcoholic fatty liver disease.

Zhang J, Li S, Li J, Han C, Wang Z, Li C, Wang X, Liu Z, Wen J, Zheng L.

Chin Med J (Engl). 2014;127(21):3771-6.

PMID:
25382334
12.

The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.

Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, Suman A, Weber M, Cusi K.

Hepatology. 2015 Jan;61(1):153-60. doi: 10.1002/hep.27395. Epub 2014 Nov 25.

PMID:
25145475
13.

Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.

Panahi Y, Ghamarchehreh ME, Beiraghdar F, Zare R, Jalalian HR, Sahebkar A.

Hepatogastroenterology. 2012 Oct;59(119):2099-2103. doi: 10.5754/hge10860.

PMID:
23234816
14.

High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.

Cai J, Wu CH, Zhang Y, Wang YY, Xu WD, Lin TC, Li SX, Wang LH, Zheng J, Sun Y, Liu W, Tao T.

Int J Obes (Lond). 2017 May 10. doi: 10.1038/ijo.2017.116. [Epub ahead of print]

PMID:
28487551
15.

Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.

Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM.

World J Gastroenterol. 2013 Oct 28;19(40):6911-8. doi: 10.3748/wjg.v19.i40.6911. Review.

16.

Prevalence and associated metabolic factors of fatty liver disease in the elderly.

Wang Z, Xu M, Peng J, Jiang L, Hu Z, Wang H, Zhou S, Zhou R, Hultström M, Lai EY.

Exp Gerontol. 2013 Aug;48(8):705-9. doi: 10.1016/j.exger.2013.05.059. Epub 2013 May 27.

PMID:
23721951
17.

Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease.

Esteghamati A, Noshad S, Khalilzadeh O, Khalili M, Zandieh A, Nakhjavani M.

Metab Syndr Relat Disord. 2011 Apr;9(2):111-7. doi: 10.1089/met.2010.0066. Epub 2010 Nov 20.

PMID:
21091060
18.

Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.

Lou DJ, Zhu QQ, Si XW, Guan LL, You QY, Yu ZM, Zhang AZ.

J Diabetes Complications. 2014 Sep-Oct;28(5):711-4. doi: 10.1016/j.jdiacomp.2014.04.008. Epub 2014 Apr 18. Erratum in: J Diabetes Complications. 2015 Jan-Feb;29(1):158. Li, Duo [Deleted].

PMID:
24927647
19.

Irisin in patients with nonalcoholic fatty liver disease.

Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS.

Metabolism. 2014 Feb;63(2):207-17. doi: 10.1016/j.metabol.2013.09.013. Epub 2013 Oct 18.

PMID:
24140091
20.

Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.

Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H.

Hepat Mon. 2012 Aug;12(8):e6099. doi: 10.5812/hepatmon.6099. Epub 2012 Aug 3.

Supplemental Content

Support Center